Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Moderna's revised 2026 outlook reflects growing confidence in its newer vaccine products, which is a positive development for investors. The company's decision to raise its revenue growth guidance suggests that its newer vaccines are gaining traction, potentially offsetting the decline in COVID-19 vaccine sales. This is a key consideration for fund managers with exposure to the biotech sector.
The upgrade comes at a critical time for Moderna, as the company navigates a shifting landscape for COVID-19 vaccines. With the pandemic now endemic, demand for COVID-19 vaccines has decreased, and Moderna has been working to diversify its portfolio with newer vaccine products. The company's progress in this area will be closely watched by investors, who are looking for signs of long-term growth and sustainability.
Looking ahead, fund managers will be monitoring Moderna's progress in commercializing its newer vaccines, including its respiratory syncytial virus (RSV) vaccine and its combination vaccine against COVID-19 and flu. The company's ability to execute on these product launches and achieve its revised revenue growth targets will be a key factor in determining its future performance and attractiveness as an investment opportunity.
Originally reported by cnbc.com. FundNews adds analysis for finance & markets readers.